Director Dealings / Market Share Purchase

RNS Number : 6083K

Oxford Biomedica PLC

11 April 2018

 

Director Dealings / Market Share Purchase

Oxford, UK - 11 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo Fund, a person closely associated with Martin Diggle, Non-Executive Director, has purchased 1,000,000 ordinary shares of 1p each ("Ordinary Shares") in the Company on 10 April 2018 on the London Stock Exchange at a price of 11.0p per share. Following this purchase Vulpes Testudo/Vulpes Life Sciences Fund holds 582,008,434 ordinary shares representing 17.7% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Vulpes Testudo Fund
2.	Reason for the notification
a.	Position/status	Person closely associated with Martin Diggle, Non-Executive Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford BioMedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford BioMedica plc Ordinary Shares of 1p each  GB0006648157
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.11	1,000,000
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	1,000,000  £0.11  £110,000.00
f.	Date of the transaction	2018-04-10
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

The issued share capital of the Group is 3,283,790,680 ordinary 1p shares.                   

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson,  Chief Executive Officer Stuart Paynter, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

DSHUARORWBASAAR